Literature DB >> 24199712

Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.

Ashish M Kamat1, Sima Porten2.   

Abstract

Intravesical therapy with bacillus Calmette-Guérin has proven effects for reducing recurrence, progression, and death from non-muscle-invasive bladder cancer. These advantages are seen mainly when appropriate maintenance therapy is used for 1-3 years, in the context of appropriate patient selection, tumor management, and symptom support for potential side effects.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24199712      PMCID： PMC4676267          DOI： 10.1016/j.eururo.2013.10.016

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  11 in total

1.  Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.

Authors:  J Palou; P Laguna; F Millán-Rodríguez; R R Hall; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

2.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

3.  Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Authors:  Jorg Oddens; Maurizio Brausi; Richard Sylvester; Aldo Bono; Cees van de Beek; George van Andel; Paolo Gontero; Wolfgang Hoeltl; Levent Turkeri; Sandrine Marreaud; Sandra Collette; Willem Oosterlinck
Journal:  Eur Urol       Date:  2012-11-02       Impact factor: 20.096

4.  Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.

Authors:  Shiro Hinotsu; Hideyuki Akaza; Seiji Naito; Seiichiro Ozono; Yoshiteru Sumiyoshi; Sumio Noguchi; Akito Yamaguchi; Satoshi Nagamori; Akito Terai; Yasutomo Nasu; Haruki Kume; Yoshihiko Tomita; Yoshinori Tanaka; Shoji Samma; Hirotsugu Uemura; Hirofumi Koga; Tomoyasu Tsushima
Journal:  BJU Int       Date:  2010-12-22       Impact factor: 5.588

5.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; J Alfred Witjes; Karlheinz Kurth
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

6.  A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

Authors:  R A Badalament; H W Herr; G Y Wong; C Gnecco; C M Pinsky; W F Whitmore; W R Fair; H F Oettgen
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

7.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

8.  Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.

Authors:  M A Hudson; T L Ratliff; D P Gillen; E O Haaff; S M Dresner; W J Catalona
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

9.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.

Authors:  Richard J Sylvester; Maurizio A Brausi; Wim J Kirkels; Wolfgang Hoeltl; Fernando Calais Da Silva; Philip H Powell; Stephen Prescott; Ziya Kirkali; Cees van de Beek; Thierry Gorlia; Theo M de Reijke
Journal:  Eur Urol       Date:  2009-12-18       Impact factor: 20.096

10.  Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

Authors:  J Alfred Witjes; Joan Palou; Mark Soloway; Donald Lamm; Ashish M Kamat; Maurizio Brausi; Raj Persad; Roger Buckley; Marc Colombel; Andreas Böhle
Journal:  BJU Int       Date:  2013-03-01       Impact factor: 5.588
View more
  10 in total

Review 1.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 2.  What is new in non-muscle-invasive bladder cancer in 2016?

Authors:  Ashish M Kamat; Murat Bağcıoğlu; Emre Huri
Journal:  Turk J Urol       Date:  2017-03-01

3.  Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

Authors:  Ashish M Kamat; Joseph Briggman; Diana L Urbauer; Robert Svatek; Graciela M Nogueras González; Roosevelt Anderson; H Barton Grossman; Ferran Prat; Colin P Dinney
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

4.  MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.

Authors:  Lin Zhu; Xianhui Liu; Weiyu Zhang; Hao Hu; Qi Wang; Kexin Xu
Journal:  BMC Cancer       Date:  2022-05-17       Impact factor: 4.638

Review 5.  Harnessing the beneficial heterologous effects of vaccination.

Authors:  Helen S Goodridge; S Sohail Ahmed; Nigel Curtis; Tobias R Kollmann; Ofer Levy; Mihai G Netea; Andrew J Pollard; Reinout van Crevel; Christopher B Wilson
Journal:  Nat Rev Immunol       Date:  2016-05-09       Impact factor: 53.106

Review 6.  Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Authors:  Charles C Peyton; Juan Chipollini; Mounsif Azizi; Ashish M Kamat; Scott M Gilbert; Phillippe E Spiess
Journal:  World J Urol       Date:  2018-12-07       Impact factor: 3.661

Review 7.  Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Dis Markers       Date:  2015-11-23       Impact factor: 3.434

8.  Bladder cancer: 2017 and beyond.

Authors:  Ashish M Kamat
Journal:  Indian J Urol       Date:  2017 Apr-Jun

Review 9.  Hope and challenge: Precision medicine in bladder cancer.

Authors:  Hongwei Su; Haitao Jiang; Tao Tao; Xing Kang; Xu Zhang; Danyue Kang; Shucheng Li; Chengxi Li; Haifeng Wang; Zhao Yang; Jinku Zhang; Chong Li
Journal:  Cancer Med       Date:  2019-03-24       Impact factor: 4.452

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.

Authors:  Matthew D Galsky; Arjun V Balar; Peter C Black; Matthew T Campbell; Gail S Dykstra; Petros Grivas; Shilpa Gupta; Christoper J Hoimes; Lidia P Lopez; Joshua J Meeks; Elizabeth R Plimack; Jonathan E Rosenberg; Neal Shore; Gary D Steinberg; Ashish M Kamat
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.